ImpediMed Limited (IPD) Earnings Call Transcripts

ImpediMed Limited's Latest Earnings Call - June 11, 2026

In the Extraordinary General Meeting held on June 11, 2026, ImpediMed Limited announced a capital raising initiative totaling $15.2 million, which includes a $3 million tranche already completed and a $10.2 million tranche pending shareholder approval. The company aims to utilize these funds for debt reduction and to invest in high-growth markets, specifically targeting breast cancer-related lymphedema, heart health, and weight management. Management indicated a strategic cost reduction of $5 million annually, signaling a focus on operational efficiency, with expectations to achieve operating cash flow breakeven by the second half of FY28.

Reported metrics

Guidance from management

Management has indicated that they expect to achieve operating cash flow breakeven by the second half of FY28, maintaining a focus on cost efficiency and growth investments.

What management said

Yes, sure. I think we were actually of the view that raising the 30,000 customary amount to 100,000 meant that we gave our shareholders more than ample opportunity to participate. So that was our that was our approach. We were much more inclined to give our current shareholders, more opportunity to participate than less. So I think given that was the underlying kind of approach, I think the scale back has may be view...

Any online questions on that item? Okay. Great. Thank you. So the next item of business is to seek approval to issue the commitment options and the resolution is put to you as displayed on the screen. And the votes received prior to the meeting are now shown on the screen. And I'll take questions on this item from within the room. And any online? Okay. Thank you. And then other items relate to the placement secur...

What analysts pressed on

Analysts expressed concerns regarding the scale back of the SPP, which may disadvantage smaller shareholders. There were questions about the rationale behind the scale back methodology and whether it could impact shareholder loyalty and participation in future capital raises.

Main topics on the call

• Capital Raising — ImpediMed is pursuing a $15.2 million capital raise, with $3 million already secured from Tranche 1 and $10.2 million pending approval for Tranche 2. Management stated, "the proceeds from the cap raise will include parti...
• Cost Reduction Initiatives — The company has implemented cost-out initiatives totaling $5 million annually, net of reinvestment in key revenue-generating functions. This strategic move aims to enhance operational efficiency and support future growth...
• Future Cash Flow Expectations — Management expects to reach operating cash flow breakeven by the second half of FY28, indicating a positive outlook on financial stability and operational performance. They stated, "assuming full exercise of the options ...
• Shareholder Participation — The share purchase plan (SPP) allows for up to 100,000 shares per shareholder, significantly increasing participation opportunities compared to the customary $30,000 limit. Management emphasized, "we were much more incli...

Read the full ImpediMed Limited transcript (June 11, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 39 ImpediMed Limited earnings call transcripts on record, spanning January 20, 2020 to July 27, 2026. Based on this history, ImpediMed Limited reports quarterly. The most recent call on file is dated July 27, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

IPD

Exchange

ASX

Country

AU

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

39

First call

January 20, 2020

Most recent

July 27, 2026

Reporting cadence

quarterly